Novavax (NVAX) Has 'Substantial Doubt' About Its Future

Novavax (NVAX) has 'substantial doubt' about its future. Caleb Silver discusses NVAX as its earnings were released February 28th. NVAX's adjusted EPS came in at -$2.28 versus an estimated -$0.92 and its revenue came in at $357.40M versus an estimated $377.64M. He talks about how NVAX warned of funding concerns and plans to reduce spending. He also goes over iShares Biotechnology ETF (IBB). Tune in to find out more about the stock market today.